Topical immunopharmacology of ocular allergies

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 5, 2002, Pages 435-445

  Bielory, Leonard ^a   Kempuraj, Duraisamy ^a   Theoharides, Theoharis ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Allergic conjunctivitis; Immunotherapy

Indexed keywords

ANTAZOLINE; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; CALCIMYCIN; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DEXAMETHASONE; EMEDASTINE; FLUOROMETHOLONE; IMMUNOGLOBULIN E ANTIBODY; KETOTIFEN; LEVOCABASTINE; LODOXAMIDE; LORATADINE; MEQUITAZINE; MIZOLASTINE; NAPHAZOLINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PERIMIROLAST POTASSIUM; PHENIRAMINE; PHENYLEPHRINE; PIPERIDINE DERIVATIVE; QUERCETIN; SUBSTANCE P; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOCON A;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CALCIUM CELL LEVEL; CELL TYPE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EYE IRRITATION; EYE PAIN; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; MAST CELL; MEDIATOR RELEASE; MYDRIASIS; NEUROTOXICITY; NONHUMAN; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PHOTOPHOBIA; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RECEPTOR BLOCKING; REVIEW; SEDATION;

EID: 0036772225     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200210000-00012     Document Type: Review

References (140)

1. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77:1033-1079.
2. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin in mast cells. Nature 1982; 297:229-231.
3. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. Clin Exp Allergy 2000; 30:1205-1212.
4. Theoharides TC. The mast cell: A neuroimmunoendocrine master player. Int J Tiss React 1996; 18:1-21.
5. Theoharides TC. Stress and mast cells: A psychoneuroimmunological perspective. J Clin Psychopharmacol 2002; 22:103-108. This recent editorial reviews clinical and experimental evidence indicating that mast cells may be activated non-immunologically, especially by peptides such as corticotrophin-releasing hormone, which could either induce the differential release of mediators or potentiate allergic stimulation.
6. Lippert U, Mooller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9:118-124.
7. Queralt M, Brazis P, Merlos M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-α release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res 2000; 49:355-360.
8. Theoharides TC, Kops SK, Bondy PK, Askenase PW. Differential release of serotonin without comparable histamine under diverse conditions in the rat mast cell. Biochem Pharmacol 1985; 34:1389-1398.
9. Nielsen PN, Skov PS, Schmetz M, Petersen LJ. Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31:1378-1384. This paper indicates that cetirizine, the metabolite of hydroxyzine, is a potent histamine-1 receptor antagonist; however, unlike hydroxyzine, cetirizine does not inhibit mast cell mediator secretion.
10. Alexander M, Rosen LJ, Yang WH. Comparison of topical nedocromil sodium and oral terfenadine for the treatment of seasonal allergic conjunctivitis. Clin Ther 1999; 21:1900-1907.
11. Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000; 230:60-63.
12. Abelson MB, Lanier RQ. The added benefit of local patanol therapy when combined with systemic claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol Scand Suppl 1999; 228:53-56.
13. Weston JH, Udell IJ, Abelson MB. H1 receptors in the human ocular surface. Invest Ophthalmol Vis Sci 1981; 20:32.
14. Abelson MB, Udell IJ. H2 receptors in the human ocular surface. Arch Ophthalmol 1981; 99:302-304.
15. Abelson MB, Paradis A, George MA, et al. Effects of vasocon-A in the allergen challenge model of allergic conjunctivitis. Arch Ophthalmol 1990; 108:522-524.
16. Federal Registers. Antazoline in fixed combination with naphazoline for human ophthalmic use: Drug efficacy study implementation; Final evaluation. Federal Register 1992; 57:45391-45392.
17. Kjellman N-IM, Andersson B. Terfenadine reduces skin and conjunctival reactivity in grass pollen allergic children. Clin Allergy 1986; 16:441-449.
18. Ciprandi G, Buscaglia S, Pesce GP, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96:344-347.
19. Bachert C, Brostoff J, Scadding GK, et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy 1998; 53:969-975.
20. Arriaga F, Rombaut N. Absence of central effects with levocabastine eyedrops. Allergy 1990; 45:552-554.
21. Leysen JE, Gommeren W. Drug receptor dissociation time, new tool for drug research: Receptor binding affinity and drug receptor dissociation profiles of serotonin S2, dopamine D2, histamine H1 antagonists and opiates. Drug Dev Res 1986; 8:119-131.
22. 1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test. Int Arch Allergy Appl Immunol 1987; 82:541-543.
23. Azevedo M, Castel-Branco MG, Oliveira JF, et al. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1991; 21:689-694.
24. Smith LM, Southwick PC, DeRosia DR, Abelson MB. The effects of levocabastine, a new highly potent and specific histamine H1 receptor antagonist, in the ocular allergen challenge model of allergic conjunctivitis [Abstract]. Invest Ophthalmol Vis Sci 1989; 30:502.
25. Pipkorn U, Bende M, Hender J, et al. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Allergy 1985; 40:491-496.
26. Van Wauve JP. Animal pharmacology of levocabastine: A new type of H1 antihistamine well suited for topical application. In: Mygind N, Naclerio RM, editors. Rhinoconjunctivitis: New Perspectives in Topical Treatment. Proceedings of the XIIIth International Congress of Allergology and Clinical Immunology. Montreux: Hogrefe & Huber Publishers; October 1988. pp. 27-34.
27. Feinberg G, Stokes TC. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine. Int Arch Allergy Appl Immunol 1987; 82:537-538.
28. Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol 1998; 8:207-216.
29. Ahluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001; 108:449-454. In a double-blind, randomized clinical trial of ocular allergy challenge, nedocromil was shown to decrease mast cell mediators in tears, whereas levocavastin had anti-histaminic action, but also reduced ICAM-1 expression by 50% in bulbar biopsies at 6 and 14 h after challenge.
30. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
31. Sharif NA, Xu S, Yanni JM. Emedastine: Pharmacological profile of a novel antihistamine for use in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1995; 36:S135.
32. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
33. Persi L, Dupin O, Arnaud B, et al. Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis. Allergy 1997; 52:451-454.
34. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
35. Hyams SW, Bialik M, Neumann E. Clinical trials of disodium cromoglycate in vernal conjunctivitis. J Pediatr Ophthalmol 1976; 12:116.
36. Theoharides TC, Sieghart W, Greengard P, Douglas, WW. Anti-allergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science 1980; 207:80-82.
37. Theoharides TC. The mast cell: A neuroimmunoendocrine master player. Int J Tiss React 1996; 18:1-21.
38. Theoharides TC, Wang L, Pang X, et al. Cloning and cellular localization of the rat mast cell 78 kD protein phosphorylated in response to the mast cell 'stabilizer' cromolyn. J Pharmacol Exp Ther 2000; 294:810-821.
39. Sorkin EM, Ward A. Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease. Drugs 1986; 31:131-148.
40. Bielory L. Ocular allergy guidelines: A practical algorithm. Drugs 2002; 62:1611-1634.
41. Campbell AM, Demoly P, Micel FB, Bousquet J. Conjunctival provocation test with codeine phosphate: Effect of disodium cromoglycate. Ann Allergy 1993; 71:51-55.
42. Juniper EF, Guyatt GH, Ferrie PJ, King DR. Sodium cromoglycate eye drops: Regular versus 'as needed' use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunol 1994; 94:36-43.
43. Leonardi A, Borghesan F, Faggian D, et al. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy 1995; 50:610-613.
44. Sorkin EM, Ward A. Ocular sodium cromoglycate: An overview of its therapeutic efficacy in allergic eye disease. Drugs 1986; 31:131-148.
45. Valdivieso R, Subiza J, Varela-Losada S, et al. Severe allergic conjunctivitis and chemosis caused by disodium cromoglycate. J Invest Allergol Clin Immunol 1998; 8:58-60.
46. Gonzalez JP, Brogden RN. Nedocromil sodium: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airway disease. Drugs 1987; 34:560-577.
47. Corin RE. Nedocromil sodium: A review of the evidence for a dual mechanism of action. Clin Exp Allergy 2000; 30:461-468.
48. Gonzalez JP, Brogden RN. Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987; 34:560-577.
49. Carolan EJ, Casale TB. Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers. Ann Allergy 1992; 69:323-328.
50. Silva PM, Martins MA, Castro-Faria-Neto HC, et al. Nedocromil sodium prevents in vivo generation of the eosinophilotactic substance induced by PAF but fails to antagonize its effects. Br J Pharmacol 1992; 105:436-440.
51. Loh R, Jabara H, Geha R. Mechanisms of inhibition of IgE synthesis by nedocromil sodium: Nedocromil sodium inhibits deletional switch recombination in human B cells. J Allergy Clin Immunol 1996; 97:1141-1150.
52. Loh R, Jabara H, Geha R. Disodium cromoglycate inhibits S mu to the S epsilon deletional switch recombination and IgE synthesis in human B cells. J Exp Med 1994; 180:663-671.
53. Kimata H, Yoshida A, Ishioha C, Mikawa H. Sodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cells in vitro. Clin Exp Immunol 1991; 84:395-399.
54. Hoyos L, Norris A, Vargaftig BB. Effects of nedocromil sodium on antigen-induced conjunctivitis in guinea pigs. Adv Ther 2000; 17:1-6.
55. Corin RE. Nedocromic sodium; a review of the evidence for a dual mechanism of action. Clin Exp Allergy 2000; 30:461-468.
56. Hammann C, Kammerer R, Gerber M, Spertini F. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen. J Allergy Clin Immunol 1996; 98:1045-1050.
57. Diebold Y, Calonge M, Carretero V, et al. Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium. J Ocul Pharmacol Ther 1998; 14:517-531.
58. van Bijsterveld OP, Moons L, Verdonck M, Kempeneers HP. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate. Ocul Immunol Inflamm 1994; 2:177-186.
59. Bijsterveld OV, Moons L, Verdonck M, Kempeneers H. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate. Ocul Immunol Inflamm 1994; 2:177-186.
60. Kjellman NI, Stevens MT. Clinical experience with tilavist: An overview of efficacy and safety. Allergy 1995; 50 (21:14-22; discussion) 34-38.
61. Verin P. Treating severe eye allergy. Clin Exp Allergy 1998; 23 (Suppl. 6):44-48.
62. Verin PH, Dicker ID, Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy 1999; 29:529-536.
63. Stockwell A, Easty D. Double blind comparative trial of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis [Abstract]. Invest Ophthalmol Vis Sci 1988; 29:229.
64. Melamed J, Schwartz RH, Hirsch SR, Cohen SH. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Ann Allergy, Asthma Immunol 1994; 73:57-66.
65. Hirsch SR, Melamed J, Schwartz RH. Efficacy of nedocromil sodium 2% ophthalmic solution in the treatment of ragweed seasonal allergic conjunctivitis. J Allergy Clin Immunol 1988; 81:173.
66. Jarmoszuk I, Blumenthal M, Silvers W, et al. Nedocromil sodium 2% ophthalmic solution in the treatment of ragweed seasonal allergic conjunctivitis. J Allergy Clin Immunol 1988; 81:174.
67. Leino M, Carlson C, Jaanio E, et al. A double bind group comparative study of 2% nedocromil sodium eye drops in the treatment of seasonal allergic conjunctivitis. Ann Allergy 1990; 64:398-402.
68. Blumenthal M, Casale T, Dockhorn R, et al. A multicenter double-blind group comparative study of the efficacy and safety of b.i.d. nedocromil sodium 2% ophthalmic solution in the treatment of allergic conjunctivitis. Am J Ophthalmol 1992; 113:56-63.
69. Leino M. Studies comparing efficacy of nedocromil sodium eye drops with sodium cromoglycate and placebo in seasonal allergic conjunctivitis. Ocul Immunol Inflamm 1993; 1:21-23.
70. Spraul CW, Lang GK. Allergic and atopic diseases of the lid, conjunctiva, and cornea. Curr Opin Ophthalmol 1995; 6:21-26.
71. Johnson HG, VanHout CA, Wright JB. Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,385E: I. Activity in rats. Int Arch Appl Allergy Immunol 1978; 56:416-423.
72. Bonini S, Schiavone M, Bonini S, et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997; 104:849-853.
73. Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997; 81:23-26.
74. Akman A, Irkec M, Orhan M. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye 1998; 12:291-295.
75. Verstappen AA, Smith J, Rosenthal A. A double-masked efficacy and safety evaluation of lodoxamide 0.1% ophthalmic solution versus opticrom 2%. A multicenter study in patients with allergic eye disorders. Alcon Report 1988; #008:34350:1287.
76. Bloch-Michel E. Evaluation de l'efficacite therapeutique d'un collyre anti-allergique par test photographique. Rev Fr Allergol 1990; 30:163-165.
77. Cerqueti PM, Ricca V, Tosca MA, et al. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol 1994; 105:185-189.
78. Bonini S, Schiavone M, Bonin S, et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997; 104:849-853.
79. Richard C, Trinquand C, Bloch-Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Eur J Ophthalmol 1998; 8:207-216.
80. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 1996; 12:401-407.
81. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
82. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996; 278:1252-1261.
83. Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999; 117:643-647.
84. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797-804.
85. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211-218.
86. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997; 79:541-545.
87. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000; 84:504-508.
88. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996; 12:389-400.
89. Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9:118-124.
90. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797-804.
91. Aguilar A. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 2000; 78:52-55.
92. Tomioka H, Yoshida S, Tanaka M, Kumagai A. Inhibition of chemical mediator release from human leukocytes by a new antiasthma drug, HC 20-511 (ketotifen). Monogr Allergy 1979; 14:313-317.
93. Nishimura N, Ito K, Tomioka H, Yoshida S. Inhibition of chemical mediator release from human leukocytes and lung in vitro by a novel antiallergic agent, KB-2413. Immunopharmacol Immunotoxicol 1987; 9:511-521.
94. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40:412-448.
95. McTavish D, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989; 38:778-800.
96. McNeely W, Wiseman LR. Intranasal azelastine. A review of its efficacy in the management of allergic rhinitis. Drugs 1998; 56:91-114.
97. Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinin receptor-binding sites. J Allergy Clin Immunol 1989; 83:771-776.
98. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997; 27:182-191.
99. Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998; 14:161-170.
100. Friedlaender MH, Harris J, LaVallee N, et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 2000; 107:2152-2157.
101. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992; 22:289-295.
102. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985; 16:318-322.
103. Busse W, Randlev B, Sedgwick J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989; 83:400-405.
104. Chand N, Nolan K, Diamantis W, et al. Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea pigs. Allergy 1986; 41:473-478.
105. Chand N, Diamantis W, Sofia RD. Modulation of in vitro anaphylaxis of guinea-pig isolated tracheal segments by azelastine, inhibitors of arachidonic acid metabolism and selected antiallergic drugs. Br J Pharmacol 1986; 87:443-448.
106. Chand N, Pillar J, Nolan K, et al. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: Implication for its mechanism of action. Int Arch Allergy Appl Immunol 1989; 90:67-70.
107. Chand N, Pillar J, Nolan K, et al. Inhibition of 5-HETE, LTB4, and LTC4 formation by azelastine in rat mixed peritoneal cells. Int Arch Allergy Appl Immunol 1990; 92:143-147.
108. Chand N, Sofia RD. Azelastine - A novel in vivo inhibitor of leukotriene biosynthesis: A possible mechanism of action: A mini review. J Asthma 1995; 32:227-234.
109. Nakata Y, Hide I. Calcium signaling and protein kinase C for TNF-alpha secretion in a rat mast cell line. Life Sci 1998; 62:1653-1657.
110. Hide I, Toriu N, Nuibe T, et al. Suppression of TNF-α secretion by azelastine in a rat mast (RBL-2H3) cell line: Evidence for differential regulation of TNF-α release, transcription, and degranulation. J Immunol 1997; 159:2932-2940.
111. Shichijo M, Inagaki N, Nakai N, et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 1998; 28:1228-1236.
112. Lytinas M, Kempuraj D, Huang M, et al. Azelastine inhibits histamine and tryptase release from human umbilical cord blood-derived cultured mast cells, as well as rat skin mast cell-induced vascular permeability: Comparison to olopatadine. Asthma Allergy Proc 2002; 23:45-51. In this study azelastine was shown to inhibit the activation of rat skin and umbilical cord-derived human mast cells.
113. Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002; 88:501-506. This is the first comparison of the serially diluted ophthalmic solutions, azelastine and olopatadine. It was shown that azelastine was more potent than olopatadine in the inhibition of tryptase and IL-6 from umbilical cord blood-derived human mast cells.
114. Kempuraj D, Basu S, Huang M, et al. Azelastine inhibits secretion of interleukin-6, interleukin-8 and TNF-α, as well as intracellular calcium ions and NFκB activation in human umbilical cord blood-derived cultured mast cells. J Allergy Clin Immunol 2002; (in press).
115. Ciprandi G, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993; 91:783-792.
116. Conti P. Anti-inflammatory actions of azelastine. Asthma Allergy Proc 2002; 23:153-155. This is a short review summarizing clinical and experimental evidence in support of the anti-inflammatory actions of azelastine.
117. Woodward DF, Nieves AL, Hawley SB, et al. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 1995; 11:339-347.
118. Woodward DF, Nieves AL, Friedlaender MH. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J Pharmacol Exp Ther 1996; 279:137-142.
119. Woodward DF, Nieves AL, Williams LS, et al. Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity. Eur J Pharmacol 1989; 164:323-333.
120. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38 (Suppl.):141-148.
121. Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997; 45:177-180.
122. Wood TS, Stewart RH, Bowman RW, et al. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 1988; 95:822-826.
123. Meyer E, Kraus E, Zonis S. Efficacy of antiprostaglandin therapy in vernal conjunctivitis. Br J Ophthalmol 1987; 71:497-499.
124. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol 1983; 95:502-505.
125. Buckley DC, Caldwell DR, Reaves TA Jr. Treatment of vernal conjunctivitis with suprofen, a topical nonsteroidal anti-inflammatory agent [Abstract]. Invest Ophthalmol Vis Sci 1986; 27:29.
126. Bishop K, Abelson M, Cheetham J, Harper D. Evaluation of flurbiprofen in the treatment of antigen-induced allergic conjunctivitis [Abstract]. Invest Ophthalmol Vis Sci 1990; 31:487.
127. Khosravi E, Elena PP, Hariton C. Allergic conjunctivitis and uveitis models: Reappraisal with some marketed drugs. Inflamm Res 1995; 44:47-54.
128. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38 (Suppl.):133-140.
129. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: A multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000; 17:94-102.
130. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998; 14:137-145.
131. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998; 14:137-145.
132. Friedlaender MH. Contact lens induced conjunctivitis: a model of human ocular inflammation. Clao J 1996; 22:205-208.
133. Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996; 103:890-892.
134. Middleton E, Kandaswami C, Theoharides TC. The effect of plant flavonoids on mammalian cells: Implications for inflammation, heart disease and cancer. Pharmacol Rev 2000; 52:673-751.
135. Tronovsky J, Letourneau R, Haggag E, et al. Quercetin-induced expression of rat mast cell protease II and accumulation of secretory granules in rat basophilic leukemia cells. Biochem Pharmacol 1993; 46:2315-2326.
136. Alexandrakis M, Singh L, Boucher W, et al. Differential effects of flavonoids on inhibition of secretion and on accumulation of secretory granules in rat basophilic leukemia cells. Int J Immunopharmacol 1999; 21:379-390.
137. Theoharides TC, Alexandrakis M, Kempuraj D, Lytinas M. Anti-inflammatory actions of flavonoids and structural requirements for new design. Int J Immunopathol Pharmacol 2001; 14:119-127. This review highlights the structural characteristics of select flavonoids required for the effective inhibition of mediator secretion from mast cells and other inflammatory cells.
138. Ennis M, Truneh A, White JR, Pearce FL. Inhibition of histamine secretion from mast cels. Nature 1981; 289:186-187.
139. Sieghart W, Theoharides TC, Douglas WW, Greengard P. Phosphorylation of a single mast cell protein in response to drugs that inhibit secretion. Biochem Pharmacol 1981; 30:2737-2738.
140. Theoharides TC, Patra P, Boucher W, et al. Chondroitin sulfate inhibits connective tissue mast cells. Br J Pharmacol 2000; 131:1039-1049.